ライフサイエンスコーパス: fetuin-A

1 hment was confined to the fractions that had fetuin-A.

2 xtracellular Ca(2+) ions as cells growing in fetuin-A.

3 in-A6, one of the cell surface receptors for fetuin-A.

4 ha, IL-6, IL-12, IL-17, malondialdehyde, and fetuin-a.

5 -Heremans-Schmid glycoprotein, also known as fetuin-A.

6 on and the only macromolecule in solution is fetuin, a 48-kDa inhibitor of apatite growth.

7 One of them is fetuin-A, a 60-kDa glycoprotein synthesized in the liver

8 Dialysis patients with low levels of serum fetuin-A, a circulating inhibitor of mineralization, hav

9 bound to alpha2-Heremans-Schmid glycoprotein/fetuin-A, a hepatocyte-specific protein associated with

10 form the first nidus for mineralization and fetuin-A, a potent circulating inhibitor of calcificatio

11 ound that both the sera of mice deficient in fetuin-A, a serum protein that inhibits calcification, a

12 ated on a mineral-rich diet, suggesting that fetuin-A acts to inhibit calcification systemically.

13 protein fraction was immunoprecipitated on a fetuin-A-adsorbed protein A column, TRAP bound this liga

14 ses' Health Study, for whom levels of plasma fetuin-A, alanine transaminase (ALT), and gamma-glutamyl

15 Serum fetuin-A also influenced the growth of LLC cells injecte

16 other desaturase-associated biomarkers (CRP, fetuin-A, ALT, and GGT) did not lead to appreciable atte

17 based on monitoring the interactions between fetuin A and NA enzyme.

18 an interorgan communication orchestrated by fetuin-A and adiponectin.

19 significant association was observed between fetuin-A and aortic stenosis (adjusted odds ratio, 1.49;

20 nverse association also was observed between fetuin-A and aortic stenosis among participants without

21 Serum fetuin-A and computed tomography-determined liver fat co

22 ether the association between high levels of fetuin-A and diabetes can be attributed to nonalcoholic

23 nsulin action in animal studies, but data on fetuin-A and diabetes risk in humans are sparse and the

24 s with microRNA and calcification inhibitors fetuin-A and matrix Gla protein suggests a novel role fo

25 anti-mineralization capacity due to reduced fetuin-A and matrix gla-protein (MGP) levels.

26 sease, we observed an inverse association of fetuin-A and mitral annular calcification.

27 The tumor cells adhered to immobilized fetuin-A and not alpha(2)-macroglobulin, its major conta

28 w levels of the calcium-regulating proteins, fetuin-A and osteopontin, have been found in the serum o

29 Interestingly, the tumor cells also took up fetuin-A and secreted it back to the medium using an unk

30 valuated the association between human serum fetuin-A and the metabolic syndrome (MetS) in a cohort o

31 ast growth factor 23, osteoprotegerin (OPG), fetuin A, and clinical and biochemical parameters.

32 immunostaining for matrix-gla-protein (MGP), fetuin-A, and ankylosis protein (Ank) as well as alkalin

33 ification in body fluids, including albumin, fetuin-A, and apolipoprotein A1.

34 icles containing the serum proteins albumin, fetuin-A, and apolipoprotein A1; the mineralization-asso

35 PAD was measured concurrent with fetuin-A, and CAC and cIMT were measured 4.6 years (mean

36 -molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured

37 ers (reflected by gamma-glutamyltransferase, fetuin-A, and sex hormone-binding globulin), markers of

38 ansferase (GGT), alanine transaminase (ALT), fetuin-A, and the algorithm-based fatty liver index (FLI

39 Importantly, anti-fetuin-A antibodies inhibited invasion of hepatocytes by

40 rum and exosome proteins, including albumin, fetuin-A, apolipoprotein-A1, alkaline phosphatase, TNFR1

41 carboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibi

42 Schmid glycoprotein, commonly referred to as fetuin-A, are reduced in ESRD, a condition associated wi

43 These studies identify fetuin A as a potential extracellular regulator of m-cal

44 These studies support the role of fetuin-A as a major growth promoter in serum that can in

45 mmation, intestinal permeability, and plasma fetuin-A as potential mechanistic links between fructose

46 alpha(2)-Heremans-Schmid glycoprotein (human fetuin A) as a binding partner for calpain domain III (D

47 n also co-localized with fluorescein-labeled fetuin A at the wound site.

48 core (beta = -0.05, p = 0.0293) but not with fetuin-A (beta = 0.04, p = 0.17).

49 vidence that the uptake of the serum protein fetuin-A by VSMC is a key event in the inhibition of ves

50 increased coronary artery calcification and fetuin-A can inhibit mineralization of vascular smooth m

51 stochemistry demonstrated that serum-derived fetuin-A co-localized with calcified human vascular smoo

52 ssion construct containing full-length mouse fetuin-A complementary DNA (cDNA), linked to a His-tag,

53 Lower serum fetuin-A concentrations are associated with valvular cal

54 Higher human fetuin-A concentrations are strongly associated with Met

55 e nucleotide polymorphisms (SNPs) related to fetuin-A concentrations by a genome-wide association stu

56 ations of the genetic determinants of plasma fetuin-A concentrations have not been conducted.

57 Mean fetuin-A concentrations were 0.47 +/- 0.10 g/L.

58 Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline.

59 We evaluated the associations among serum fetuin-A concentrations, mitral annular calcification, a

60 Participants were categorized by tertiles of fetuin-A concentrations.

61 divided participants into quartiles by serum fetuin-A concentrations.

62 t prevalent clinical CVD, we measured plasma fetuin-A concentrations.

63 ent on the presence of the sialoglycoprotein fetuin, a constituent of bovine serum.

64 We could demonstrate that fetuin-A-containing CPPs facilitate the clearance of min

65 In mice, fetuin-A-containing CPPs were rapidly cleared by the ret

66 r, onset of malaria infection was delayed in fetuin-A-deficient mice compared to that in wild-type C5

67 results suggest that normalization of serum fetuin-A, either through gene therapy approaches or by d

68 In addition, fetuin-A enhanced phagocytosis of vesicles by VSMC.

69 Mice that lack fetuin-A exhibit extensive soft tissue calcification, wh

70 and bone metastasis samples displayed robust fetuin-A expression, and we demonstrated serum immune re

71 ent analyses were done to define the role of fetuin-A (Fet) in mammary tumorigenesis using the polyom

72 betic patients showed significantly elevated fetuin-A (FetA) levels in respect to their controls; par

73 Functional studies of Fetuin-A (FetA) were conducted by using gene silencing i

74 Plasma fetuin-A (g/l +/- SD) was highest in women using oral es

75 pants (80 of 177) in the highest quartile of fetuin-A had MetS compared with 24% of participants (42

76 type 2 diabetes, and AHSG, the gene encoding fetuin-A, has been identified as a susceptibility locus

77 Human fetuin A (HFA) plays a prominent pathophysiological role

78 IA) was developed for the detection of human fetuin A (HFA), a specific biomarker for hepatocellular

79 (IVD) procedure has been developed for human fetuin A (HFA), an important disease biomarker for infla

80 the site-specific modification of endogenous fetuin A in human plasma, the synthesis of tandem fluoro

81 th, we showed that LLC tumor cells adhere to fetuin-A in a Ca(2+)-dependent fashion, resulting in gro

82 olonization responded to the levels of serum fetuin-A in a dose-dependent manner, as observed by the

83 tested the hypothesis that overexpression of fetuin-A in Abcc6(-/-) mice counteracts the ectopic mine

84 ctor in circulation, and the serum levels of fetuin-A in patients with PXE as well as in a mouse mode

85 In conclusion, levels of fetuin-A in plasma are strongly associated with SNPs in

86 to our knowledge the first study implicating fetuin-A in prostate cancer and indicating that autoanti

87 together, our data show the significance of fetuin-A in tumor cell growth mechanisms in vitro and op

88 The presence of fetuin-A in vesicles abrogated their ability to nucleate

89 Fetuin A increased resealing of scrape-damaged wild-type

90 The liver-secreted protein fetuin-A induces peripheral insulin resistance in vitro.

91 To examine the mechanism by which fetuin-A influences LLC colonization and growth, we show

92 Fetuin-A inhibited in vitro VSMC calcification, induced

93 Fetuin-A interferes with insulin action in animal studie

94 However, the processes of fetuin-A intracellular trafficking and MV biogenesis are

95 However, fetuin-A inverted these benign effects of RSFC from an a

96 Fetuin-A is a circulating inhibitor of calcium depositio

97 Fetuin-A is a hepatic secretory protein and a novel risk

98 Fetuin-A is a hepatic secretory protein that binds the i

99 Fetuin-A is a hepatic secretory protein that inhibits ar

100 Fetuin-A is a liver-derived plasma protein involved in t

101 Fetuin-A is a multifunctional hepatic secretory protein

102 Fetuin-A is a multifunctional hepatic secretory protein

103 n cell culture model systems have shown that fetuin-A is a powerful anti-mineralization factor in cir

104 Fetuin-A is a serum glycoprotein in the cystatin family

105 Whereas fetuin-A is an established tumor antigen in several type

106 Higher fetuin-A is associated with incident diabetes mellitus i

107 Among well-functioning older persons, serum fetuin-A is associated with incident diabetes, independe

108 Plasma fetuin-A is associated with type 2 diabetes, and AHSG, t

109 Whether fetuin-A is associated with valvular calcification in ot

110 Biochemical studies showed that fetuin-A is essential for the formation of protein-miner

111 models with follow-up through 2012, a higher fetuin-A level was associated with a higher risk of diab

112 d with a 0.06 g/l ( approximately 13%) lower fetuin-A level.

113 ar protein kinase C theta activity and serum fetuin A levels.

114 1,025 women (median age = 73 years) who had fetuin-A levels and CVD risk factors evaluated in 1992 t

115 sitive association was observed between high fetuin-A levels and diabetes risk: the relative risk (95

116 Lower fetuin-A levels are associated with arterial calcificati

117 Lower fetuin-A levels are independently associated with greate

118 se-cohort study, we retrospectively measured fetuin-A levels in baseline serum among 406 randomly sel

119 ggest that in the presence of NAFLD elevated fetuin-A levels may impair renal function by RSF-induced

120 Low fetuin-A levels predicted greater risk for CVD mortality

121 tive risk (95% CI) comparing high versus low fetuin-A levels was 1.69 (1.39-2.05) (P for heterogeneit

122 In a pilot study, we observed that higher fetuin-A levels were associated with diabetes mellitus i

123 or cross-sectional studies in humans, higher fetuin-A levels were associated with insulin resistance.

124 Lower fetuin-A levels were associated with older age, but with

125 These findings suggest that plasma fetuin-A levels were independently associated with highe

126 Fetuin-A levels were inversely associated with CAC sever

127 We examined the association of fetuin-A levels with approximately 2.5 million genotyped

128 s to evaluate the prospective association of fetuin-A levels with cardiovascular disease (CVD) mortal

129 Participants with fetuin-A levels within the highest tertile (> 0.97 g/L)

130 iant alone explained 14% of the variation in fetuin-A levels.

131 s many colonies in mice heterozygous for the fetuin-A locus compared with homozygous WT mice and rest

132 vo study we hypothesized that the hepatokine fetuin-A may impair renal function in non alcoholic fatt

133 at maintaining normal circulating levels of fetuin-A may prove beneficial in patients with ESRD.

134 Fetuin-A may provide novel insight into mechanisms leadi

135 Fetuin-A may represent an important inhibitor of dystrop

136 If confirmed, fetuin-A might mark calcium deposition within the vascul

137 Fetuin, a negative acute-phase protein, recently was imp

138 onsistent with the yeast two-hybrid studies, fetuin A neither stabilized mu-calpain nor prevented its

139 ecting Lewis lung carcinoma (LLC) cells into fetuin-A null and their wild-type (WT) littermate contro

140 o the lungs within 2 weeks in the WT but not fetuin-A null mice.

141 metastatic nodules, whereas the lungs of the fetuin-A null mutant mice were virtually free of colonie

142 enced the growth of LLC cells injected s.c.: fetuin-A-null mice developed small s.c. tumors only afte

143 y the administration of purified fetuin-A to fetuin-A-null mice.

144 The effect of fetuin A on calpain-mediated plasma membrane resealing w

145 extracellular region of TRAP interacts with fetuin-A on hepatocyte membranes and that this interacti

146 rough distinct molecular mechanisms, such as fetuin-A, osteopontin, and bone morphogenic protein 7, a

147 % versus -13.6% versus 9.1%) and increase of fetuin-a (P<0.01).

148 ee consumption was inversely associated with fetuin-A (P-trend = 0.06) and CRP in women and gamma-glu

149 d bone osteoclastic activity, and lower free fetuin-A, plasma pyrophosphate, and albumin concentratio

150 Future studies should evaluate whether fetuin-A predicts coronary artery disease risk.

151 ratio for CVD mortality comparing the lowest fetuin-A quartile with all higher values was 1.76 (95% c

152 Higher fetuin-A quartiles were also strongly and independently

153 e odds ratio (OR) (95% CI) comparing extreme fetuin-A quintiles was 1.81 (1.07-3.06) (P for trend = 0

154 rrelated with a 65 to 75% reduction in serum fetuin, a reduction that appears to be caused by the cle

155 To study effects of the crosstalk between fetuin-A, RSF and kidney, human renal sinus fat cells (R

156 Our studies demonstrate that fetuin, a serum glycoprotein that is abundant in the fet

157 indicating that autoantibodies specific for fetuin-A show utility as a prognostic indicator for pros

158 Bovine fetuin A stabilized proteolytic activity of purified m-c

159 g participants without diabetes, the highest fetuin-A tertile had a significantly lower odds of aorti

160 Those within the highest fetuin-A tertile had significantly lower odds of mitral

161 lonization by the administration of purified fetuin-A to fetuin-A-null mice.

162 Addition of fetuin-A to the culture system prevented the mineralizat

163 The attachment of tumor cells to fetuin-A was accompanied by phosphatidylinositol 3-kinas

164 Each 0.10-g/L (SD)-greater fetuin-A was associated with 19 higher risk of diabetes

165 ordinal logistic regression, each SD higher fetuin-A was associated with 31% lower odds of CAC sever

166 The interaction of cells with fetuin-A was driven mainly by Ca(2+) ions, and cells gro

167 were expressed locally in vibrissae, whereas fetuin-A was expressed highly in the liver.

168 Alexa488-labeled fetuin-A was internalized by human VSMCs, trafficked via

169 tron microscopy-immunogold demonstrated that fetuin-A was internalized by VSMC and concentrated in in

170 f age without diabetes mellitus at baseline, fetuin-A was measured in serum collected in 1992 to 1993

171 In contrast, no association of fetuin-A was observed with PAD or high common or interna

172 Subsequently, fetuin-A was secreted via vesicle release from apoptotic

173 (ALT), aspartate aminotransferase (AST) and fetuin-A were determined in fasting blood samples and th

174 Levels of fetuin-A were slightly decreased in Abcc6-/- serum, and

175 In the present analyses, we showed that fetuin-A, whose function in cellular attachment in tissu

176 In contrast, the association of fetuin-A with aortic stenosis was modified by the presen

177 d we demonstrated serum immune reactivity to fetuin-A with concomitant development of metastatic cast

178 The association of fetuin-A with CVD mortality differed by diabetes status

179 bserved a particularly strong association of fetuin-A with diabetes risk in women that could not be e

180 We sought to confirm the association of fetuin-A with incident diabetes mellitus in older person

181 gression models evaluated the association of fetuin-A with incident diabetes mellitus.

182 However, the longitudinal association of fetuin-A with incident type 2 diabetes mellitus is unkno

183 No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or

184 is study was to determine the association of fetuin-A with subclinical cardiovascular disease (CVD) i

185 The association of fetuin-A with subclinical CVD in the general population